Angeion: Life After St. Jude
Angeion thought it was going to get to the implantable defibrillator market with St. Jude as a marketing partner. But St. Jude's acquisition of Ventritex changed all that. Now, Angeion is going it alone, with worldwide royalty-free licenses from St. Jude on a wide range of patents. But can Angeion use that base and what company officials believe is superior technology to succeed in a market increasingly dominated by giants?
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.